Clinical trial NCT02477631 - References

Iron Overload Due to Repeated Red Blood Cell Transfusions — Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients

Citation(s)

•   Cermak J, Jonasova A, Vondrakova J, Cervinek L, Belohlavkova P, Neuwirtova R
  A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes. Leuk Res. 2013 Dec;37(12):1612-5. doi: 10.1016/j
•   Cermak J, Jonasova A, Vondrakova J, Walterova L, Hochova I, Siskova M, Neuwirtova R
  Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome. Hemoglobin. 2011;35(3):217-27. doi: 10.3109/03630
•   Cermák J
  Erythropoietin administration may potentiate mobilization of storage iron in patients on oral iron chelation therapy. Hemoglobin. 2006;30(1):105-12.
•   Choi SO, Cho YS, Kim HL, Park JW
  ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBPalpha and STAT-3. Biochem Biophys Res Commun. 2007 Apr 27;356(1):312-7. Epub 2007 Mar 5.
•   Farquhar MJ, Bowen DT
  Oxidative stress and the myelodysplastic syndromes. Int J Hematol. 2003 May;77(4):342-50. Review.
•   Gattermann N, Rachmilewitz EA
  Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol. 2011 Jan;90(1):1-10. doi: 10.1007/s00277-010-1091-1. Epub 2010 Oct 12. Review.
•   Ghoti H, Amer J, Winder A, Rachmilewitz E, Fibach E
  Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome. Eur J Haematol. 2007 Dec;79(6):463-7. Epub 2007 Nov 1.
•   Greenberg PL, Young NS, Gattermann N
  Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2002:136-61. Review.
•   Hellström-Lindberg E
  Management of anemia associated with myelodysplastic syndrome. Semin Hematol. 2005 Apr;42(2 Suppl 1):S10-3. Review.
•   Hershko C, Link G, Cabantchik I
  Pathophysiology of iron overload. Ann N Y Acad Sci. 1998 Jun 30;850:191-201. Review.
•   Kersten MJ, Lange R, Smeets ME, Vreugdenhil G, Roozendaal KJ, Lameijer W, Goudsmit R
  Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Ann Hematol. 1996 Nov;73(5):247-52.
•   Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR
  Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994 Sep 1;331(9):574-8.
•   Payne KA, Rofail D, Baladi JF, Viala M, Abetz L, Desrosiers MP, Lordan N, Ishak K, Proskorovsky I
  Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. Adv Ther. 2008 Aug;25(8):725-42. doi: 10
•   Smeets ME, Vreugdenhil G, Holdrinet RS
  Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis. Am J Hematol. 1996 Mar;51(3):243-4.
•   Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B
  Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000 Sep;110(4):971-7.

The Effect of Treatment With the Oral Iron Chelator Deferiprone on the Oxidative Stress of Blood Cells and on Iron Overload Status in Transfusion Dependent, Iron-overloaded Patients With Low Risk Myelodysplastic Syndrome

Details for clinical trial NCT02477631